Janux Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €210.55M +329.4% -€175.36M -25.1% -83.3% +3.9 pp N/A N/A
    (estimated) €49.03M +923.6% -€234.02M +5.6% -477.3% +41 pp N/A N/A
    (estimated) €4.79M -3.0% -€221.51M +29.8% -4,624.3% -12 pp N/A N/A
    (estimated) €4.94M +63.7% -€170.63M +43.0% -3,456.4% +5.0 pp N/A N/A
    (estimated) €3.02M -66.9% -€119.36M +100.8% -3,958.3% -33 pp N/A N/A
    €9.12M +31.0% -€59.44M +18.4% -651.6% +0.70 pp -€37.44M -10.8% -410.4% +1.9 pp
    €6.96M -6.1% -€50.22M +7.6% -721.2% -0.92 pp -€41.98M +33.6% -602.8% -1.8 pp
    €7.42M +136.8% -€46.66M +66.3% -628.8% +2.7 pp -€31.43M +135.4% -423.6% +0.025 pp
    €3.13M +∞% -€28.05M +519.6% -895.2% -9.0 pp -€13.35M +254.6% -426.0% -4.3 pp
    €0.00 +NaN% -€4.53M +24.0% N/A -€3.76M +14.1% N/A
    €0.00 -€3.65M N/A -€3.30M N/A

    Notifications